Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs.
Journal
Clinical immunology communications
ISSN: 2772-6134
Titre abrégé: Clin Immunol Commun
Pays: United States
ID NLM: 9918697481206676
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
31
01
2023
accepted:
02
02
2023
medline:
28
11
2023
pubmed:
28
11
2023
entrez:
28
11
2023
Statut:
ppublish
Résumé
We analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vaccination. Although DMTs such as fingolimod and anti-CD20+ treatments prevented patients from developing a robust humoral response to the vaccine, most of them were still able to develop a cellular response, which could be crucial for long-term immunity. It is probably advisable that all MS patients take additional/booster doses to increase their humoral and/or cellular immune response to SARS-CoV-2.
Identifiants
pubmed: 38014396
doi: 10.1016/j.clicom.2023.02.001
pii: S2772-6134(23)00001-X
pmc: PMC9898989
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6-13Informations de copyright
© 2023 Published by Elsevier Inc.
Déclaration de conflit d'intérêts
L.E-P., N.R., F.S-M, and A.A. declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurology. 2015 Mar 3;84(9):872-9
pubmed: 25636714
EBioMedicine. 2021 Nov;73:103636
pubmed: 34666226
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
J Neuroimmunol. 2021 Dec 15;361:577746
pubmed: 34655991
Curr Opin Neurol. 2021 Jun 1;34(3):322-328
pubmed: 33709979
Nat Rev Immunol. 2021 Aug;21(8):475-484
pubmed: 34211186
N Engl J Med. 2006 Sep 14;355(11):1124-40
pubmed: 16971719
Neurology. 2020 Oct 6;95(14):e1999-e2008
pubmed: 32727835
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
JAMA Neurol. 2021 Jun 1;78(6):699-708
pubmed: 33739362
Front Immunol. 2022 Jan 19;12:755891
pubmed: 35126347
Lancet. 2021 Jul 31;398(10298):385-387
pubmed: 34274038
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Nat Commun. 2021 Aug 17;12(1):5061
pubmed: 34404775
Eur J Neurol. 2021 Nov;28(11):3712-3721
pubmed: 34152073
Mult Scler Relat Disord. 2021 Jul;52:102983
pubmed: 33990054
J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):24-31
pubmed: 34341142
Ther Adv Neurol Disord. 2019 Apr 01;12:1756286419836571
pubmed: 30967901
Drugs. 2014 Apr;74(6):659-74
pubmed: 24740824
Mult Scler. 2021 Mar;27(3):347-359
pubmed: 32940128
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
iScience. 2021 Sep 24;24(9):103078
pubmed: 34490414
Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11058-63
pubmed: 15263094
MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1545-1552
pubmed: 34735422
Neurol Ther. 2019 Dec;8(2):241-250
pubmed: 31677060
CNS Neurosci Ther. 2019 Feb;25(2):245-254
pubmed: 30044050
Immunity. 2021 Feb 9;54(2):340-354.e6
pubmed: 33567252
PLoS One. 2012;7(4):e34103
pubmed: 22496780
J Cell Immunol. 2021;3(2):68-77
pubmed: 33959727
J Immunol. 2017 Apr 15;198(8):3069-3080
pubmed: 28258191